A potential sickle-cell disease drug being developed by the biotechnology company and Pfizer failed in a key study. Allakos Inc., up $34.26 to $65.26.
News
- Tyson Foods, Allakos rise; Cars.com, ON Semiconductor fall
- Assembly Biosciences: 2Q Earnings Snapshot
CARMEL, Ind. (AP) _ Assembly Biosciences Inc. (ASMB) on Monday reported a loss of $18.5 million in its second quarter. The Carmel, Indiana-based ...
- Acceleron: 2Q Earnings Snapshot
The clinical stage biotech developing protein therapeutics for cancer and rare diseases posted revenue of $27.7 million in the period, beating Street ...
- 'Dancing for a Cause' to highlight Blood & Tissue Center Foundation's annual Red and White Ball ...
23 at the JW Marriott San Antonio Hill Country Resort & Spa. ... the lifesaving work of San Antonio-based nonprofit biomedical organization BioBridge ...
- UVA researcher working to engineer 'gut bugs' for health
"I fell in love with the science of the process," said Medlock, who, at 27, recently earned his Ph.D. in biomedical engineering from UVA. His love of ...